Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
01 mai 2017 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
17 mars 2017 07h55 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
16 mars 2017 07h15 HE
|
Proteon Therapeutics, Inc.
- Efficacy endpoints reordered and co-primary endpoints established -- Ongoing trial, if successful, expected to serve as single pivotal study for BLA submission - - Conference Call Scheduled for...
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
09 mars 2017 08h00 HE
|
Abiomed
DANVERS, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary...
Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting
06 févr. 2017 17h00 HE
|
Proteon Therapeutics, Inc.
Review results of PATENCY-1, the Phase 3 trial of investigational vonapanitase Data on impact of fistula outcomes on Medicare costs WALTHAM, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Proteon...
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
13 déc. 2016 07h00 HE
|
Proteon Therapeutics, Inc.
- Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing - - Conference Call Scheduled for 8:30 AM ET - WALTHAM,...
Proteon Therapeutics to Participate in Two Upcoming Investor Conferences
09 nov. 2016 16h35 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2016 Financial Results
07 nov. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
20 oct. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
01 sept. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...